In the field of hematologic malignancies, the first bispecific T-cell engager (BiTE) blinatumomab, a CD19- and CD3-targeted bispecific antibody, achieved complete remission with 6.7 month-long duration in 32% of the patients with B-cell lymphoblastic leukemia (B-ALL) in a clinical study [2] and has shown efficacy in non-Hodgkin lymphomas (NHLs) [3,4]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.